CRISPR Therapeutics AG (CRSP) EV to EBITDA (2016 - 2026)

CRISPR Therapeutics AG has disclosed EV to EBITDA across 11 years of filings, most recently posting 24.79 for Q2 2026.

• In Q2 2026, EV to EBITDA fell 120.6% year-over-year to 24.79; the TTM figure through Jun 2026 stood at 5.44 (down 16.64% YoY), while the FY2025 annual figure was 4.59, down 45.71% from the prior year.
• EV to EBITDA came in at 24.79 for Q2 2026 at CRISPR Therapeutics AG, down from 16.46 in the prior quarter.
• In the past five years, EV to EBITDA ranged from a high of 47.67 in Q4 2023 to a low of 31.56 in Q3 2025.
• Average EV to EBITDA over 5 years is 15.24, with a median of 17.39 recorded in 2022.
• Year-over-year, EV to EBITDA tumbled 213.89% in 2022 and surged 555.65% in 2023.
• Over 5 years, EV to EBITDA stood at 10.46 in 2022, then jumped by 555.65% to 47.67 in 2023, then plunged by 147.77% to 22.77 in 2024, then climbed by 13.38% to 19.73 in 2025, then fell by 25.69% to 24.79 in 2026.
• Per Business Quant data, the three most recent EV to EBITDA figures were 24.79 in Q2 2026, 16.46 in Q1 2026, and 19.73 in Q4 2025.